ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
The complex four-hour surgery was performed by a multidisciplinary team of doctors
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Subscribe To Our Newsletter & Stay Updated